114 related articles for article (PubMed ID: 8093809)
1. Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment.
Mayeux R; Stern Y; Tang MX; Todak G; Marder K; Sano M; Richards M; Stein Z; Ehrhardt AA; Gorman JM
Neurology; 1993 Jan; 43(1):176-82. PubMed ID: 8093809
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.
Wannamethee SG; Sirivichayakul S; Phillips AN; Ubolyam S; Ruxrungtham K; Hanvanich M; Phanuphak P
Int J Epidemiol; 1998 Apr; 27(2):289-95. PubMed ID: 9602412
[TBL] [Abstract][Full Text] [Related]
3. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with survival in human immunodeficiency virus-infected patients with very low CD4 counts.
Colford JM; Ngo L; Tager I
Am J Epidemiol; 1994 Jan; 139(2):206-18. PubMed ID: 7905248
[TBL] [Abstract][Full Text] [Related]
5. Rate of CD4 decline and neuropsychological performance in HIV infection.
Bornstein RA; Nasrallah HA; Para MF; Fass RJ; Whitacre CC; Rice RR
Arch Neurol; 1991 Jul; 48(7):704-7. PubMed ID: 1677559
[TBL] [Abstract][Full Text] [Related]
6. The effects on survival of early treatment of human immunodeficiency virus infection.
Graham NM; Zeger SL; Park LP; Vermund SH; Detels R; Rinaldo CR; Phair JP
N Engl J Med; 1992 Apr; 326(16):1037-42. PubMed ID: 1347907
[TBL] [Abstract][Full Text] [Related]
7. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group.
Ellis RJ; Deutsch R; Heaton RK; Marcotte TD; McCutchan JA; Nelson JA; Abramson I; Thal LJ; Atkinson JH; Wallace MR; Grant I
Arch Neurol; 1997 Apr; 54(4):416-24. PubMed ID: 9109743
[TBL] [Abstract][Full Text] [Related]
8. Predictors of the risk of development of acquired immunodeficiency syndrome within 24 months among gay men seropositive for human immunodeficiency virus type 1: a report from the Multicenter AIDS Cohort Study.
Saah AJ; Muñoz A; Kuo V; Fox R; Kaslow RA; Phair JP; Rinaldo CR; Detels R; Polk BF
Am J Epidemiol; 1992 May; 135(10):1147-55. PubMed ID: 1352940
[TBL] [Abstract][Full Text] [Related]
9. Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death.
Sacktor NC; Bacellar H; Hoover DR; Nance-Sproson TE; Selnes OA; Miller EN; Dal Pan GJ; Kleeberger C; Brown A; Saah A; McArthur JC
J Neurovirol; 1996 Dec; 2(6):404-10. PubMed ID: 8972422
[TBL] [Abstract][Full Text] [Related]
10. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men.
Burack JH; Barrett DC; Stall RD; Chesney MA; Ekstrand ML; Coates TJ
JAMA; 1993 Dec; 270(21):2568-73. PubMed ID: 7901433
[TBL] [Abstract][Full Text] [Related]
11. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.
Volberding PA; Lagakos SW; Grimes JM; Stein DS; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS; Phair JP; Mitsuyasu RT
JAMA; 1994 Aug; 272(6):437-42. PubMed ID: 7913730
[TBL] [Abstract][Full Text] [Related]
12. Dietary micronutrient intake and risk of progression to acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus type 1 (HIV-1)-infected homosexual men.
Tang AM; Graham NM; Kirby AJ; McCall LD; Willett WC; Saah AJ
Am J Epidemiol; 1993 Dec; 138(11):937-51. PubMed ID: 7903021
[TBL] [Abstract][Full Text] [Related]
13. Improvement of the predictive value of CD4+ lymphocyte count by beta 2-microglobulin, immunoglobulin A and erythrocyte sedimentation rate. The Multicentre Cohort Study Group.
Schwartländer B; Bek B; Skarabis H; Koch J; Burkowitz J; Koch MA
AIDS; 1993 Jun; 7(6):813-21. PubMed ID: 8103341
[TBL] [Abstract][Full Text] [Related]
14. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
[TBL] [Abstract][Full Text] [Related]
15. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
Chaisson RE; Moore RD; Richman DD; Keruly J; Creagh T
Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634
[TBL] [Abstract][Full Text] [Related]
16. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors.
De Ronchi D; Faranca I; Berardi D; Scudellari P; Borderi M; Manfredi R; Fratiglioni L
Arch Neurol; 2002 May; 59(5):812-8. PubMed ID: 12020265
[TBL] [Abstract][Full Text] [Related]
18. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.
Gallant JE; Moore RD; Richman DD; Keruly J; Chaisson RE
Arch Intern Med; 1994 Mar; 154(5):566-72. PubMed ID: 8122950
[TBL] [Abstract][Full Text] [Related]
20. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy.
Sparano JA; Hu X; Wiernik PH; Sarta C; Reddy DM; Hanau L; Henry DH
J Natl Cancer Inst; 1997 Feb; 89(4):301-7. PubMed ID: 9048834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
